




Unaudited Group interim results

for the six months ended **31 March 2024**,
and cash dividend declaration



HIGHLIGHTS



Leading provider of value-based care

Patient-centred care through innovative contracting and reimbursement models



Diversified offering

With an expansion into integral diagnostic and adjacent lines of business



People centred and patient insight driven

Positively impacting patient care through a focus on our employees, clinicians, and the utilisation of data analysis and technology

Southern Africa (SA)

Acute PPD¹ growth

↑ 2.7%

Revenue growth

↑ 5.9%

Q2-2024 margin

↑ >17%

Concluded FMC² acquisition

Life Molecular Imaging (LMI)

Increase in doses sold

↑ 74.4%

Revenue growth

↑ 77.5%

Full reimbursement for NeuraCeq® in the US

Group

Revenue growth

↑ 7.8%

Net debt / normalised EBITDA³

0.8x

NEPS

↑ 8.4%

Interim dividend

↑ 11.8 %

¹ Paid patient days

² Fresenius Medical Care

³ Post special dividend payment of R8.8bn

Making life better

HIGHLIGHTS: OUTLOOK STATEMENT FY2024 PROGRESS

Southern Africa	<ul style="list-style-type: none"> ▪ Increase occupancies ▪ Targeting PPD growth of c.3% ▪ Grow non-acute services: <ul style="list-style-type: none"> ▪ Additional imaging transactions ▪ Conclude FMC acquisition ▪ Increase intensive care unit (ICU) beds to meet high acuity demand ▪ Maintain EBITDA margin ▪ Focus on cost reduction 	<ul style="list-style-type: none"> ▪ ✓ 67.0% vs 65.9% ▪ ✓ 2.3% (acute 2.7%) <ul style="list-style-type: none"> ▪ ✓ Imaging deal at Life Hilton Private Hospital ▪ ✓ FMC concluded ▪ ✓ 59 ICU/high care (HC) beds to be added in 2024/2025 ▪ - Q2 margin > 17% ▪ ✓ Initiatives in progress
Life Molecular Imaging	<ul style="list-style-type: none"> ▪ Increase NeuraCeq® commercial sales ▪ Strengthening the US commercial organisation ▪ Invest in equipment for NeuraCeq® manufacturing ▪ Invest in tau tracer product 	<ul style="list-style-type: none"> ▪ ✓ 110% increase in commercial sales ▪ ✓ Re-organised US team with sales focus ▪ ✓ Spent USD0.9m ▪ ✓ Invested USD1.8m
Group	<ul style="list-style-type: none"> ▪ Conclude the AMG disposal ▪ Optimise cost base ▪ Distribution to shareholders 	<ul style="list-style-type: none"> ▪ ✓ Concluded ▪ ✓ In progress ▪ ✓ Paid on 8 April 2024

Making life better

Life Healthcare

STRATEGY




GROUP OVERVIEW

DIVERSIFIED OFFERING

Southern Africa

- 63 healthcare facilities
- 8 308 hospital beds
- 602 mental health beds
- 287 rehabilitation beds
- 1 145 renal dialysis stations
- 5 oncology centers
- Imaging services at 7 acute hospitals
- 2 958 PPP¹ beds
- Employer based on-site healthcare services


¹ Public-private partnerships



International

- 49 active and contracted third party manufacturing sites around the world

Making life better



Making life better




SA OPERATIONAL REVIEW




H1-2024| SOUTHERN AFRICA

	H1-2024 R'm	H1-2023 R'm	% change
Revenue	11 228	10 598	5.9
Acute hospitals	9 698	9 190	5.5
Complementary services	834	773	7.9
Healthcare services (HCS)	696	635	9.6
Normalised EBITDA	1 758	1 842	(4.6)
Acute hospitals	1 451	1 528	(5.0)
Complementary services	176	186	(5.4)
Healthcare services (HCS)	94	83	13.3
Corporate	37	45	(17.8)
Normalised EBITDA margin including corporate	15.7%	17.4%	




- Activities:
 - PPD growth of 2.3%¹ resulting in occupancies improving to 67.0%
- Revenue growth:
 - Acute business impacted by negative case mix
 - Complementary business driven by good growth in renal dialysis and imaging
- Robust performance from Life Nkanyisa and continued improvement in Life Health Solutions
- EBITDA margins impacted by higher operating costs and lower than expected activities in Q1
- Number of efficiency initiatives implemented with a stronger Q2 performance

¹ Excludes PPDs of two facilities closed in H1-2023




Making life better


H1 Occupancy %



Q1 & Q2 Occupancy %



Monthly occupancy %




Revenue:	5.5%	→	PPD growth of 2.7% and revenue/PPD of 2.8%
Occupancy %:	66.6%	→	Good Q2 2024 performance
PPD growth ¹ :	2.7%	→	Good underlying growth but negatively impacted by a quiet Q1 and March holidays
Theatre minutes:	0.9%		
Revenue/PPD:	2.8%	→	Above CPI tariff increase in January and a negative case mix


¹ On a like-for-like basis

H1-2024| COMPLEMENTARY SERVICES


Mental health & acute rehabilitation occupancy (%)



Renal dialysis (RD) treatments



MRI/CT/PET-CT/Spect scan volumes




- Revenue: 7.9% → Driven by good renal dialysis and imaging growth
- Occupancy %: 70.4% → Improvement in Q2 for mental health – 76.4%
- PPD growth¹: (1.1%) → Impacted by slow Q1
- Renal dialysis treatments: 8.5% → Benefitting from improved renal dialysis integrated care programme compliance
- MRI/CT/PET-CT/SPECT: 17.9% → Hilton radiology from 1 March 2024 and benefitting from TheraMed transaction. 8% underlying imaging growth (ignoring acquisitions)

¹ On a like-for-like basis

Making life better

H1-2024| COMPLEMENTARY SERVICES – RENAL DIALYSIS



■ FMC acquisition:

- 26 February 2024 SA competition commission (CC) approval
- 1 April 2024 operational for SA
- Cash consideration of R367m paid for SA business
- Broadened countrywide footprint
- Expanded the patient base
- Initial focus on operationalising the business and rolling out integrated care programme


	Life Healthcare	FMC	Total
Units	31	43	74
Stations	445	700	1 145
Patients	c.1 700	c.2 300	c.4 000
Annual treatments	c.200 000	c.320 000	c.520 000

Making life better

2024| SOUTHERN AFRICA – TRADING TO END APRIL

	H1-2024	%	YTD Apr 2024	YTD Apr 2023	%
	R'm	change	R'm	R'm	change
Revenue	11 228	5.9	13 267	12 328	7.6
Acute hospitals	9 698	5.5	11 484	10 681	7.5
Complementary services	834	7.9	975	899	8.5
Healthcare services	696	9.6	808	748	8.0
Normalised EBITDA	1 758	(4.6)	2 085	2 112	(1.3)
Acute hospitals	1 451	(5.0)	1 715	1 751	(2.1)
Complementary services	176	(5.4)	203	212	(4.2)
Healthcare services	94	13.3	109	96	13.5
Corporate	37	(17.8)	58	53	9.4
Normalised EBITDA margin including corporate	15.7%		15.7%	17.1%	

	Mar/Apr 2024	Mar/Apr 2023	%
	R'm	R'm	change
Revenue	4 035	3 766	7.1
Normalised EBITDA	1 758	1 842	(1.1)
Normalised EBITDA margin	17.5%	18.6%	



- YTD acute PPD growth: 2.2%¹
- YTD occupancy: 67.6% (PY 66.3%)
- Margin improvement continued into April
- Mar/Apr combined results show good revenue growth vs PY and a margin of 17.5%



¹ Exclude PPDs of two facilities closed in H1-2023



LIFE MOLECULAR IMAGING (LMI) REVIEW



LMI| ACTIVITIES AND SALES BREAKDOWN




- **Core activities - Commercial sales of NeuraCeq®**
 - LMI is engaged in selling NeuraCeq®, a PET* diagnostic imaging agent with full FDA approval marketed in USA, Europe and several other geographies
- **Research and development (R&D) portfolio development:**
 - LMI is engaged in developing a promising portfolio of five assets. 2 products are in late stage of clinical development (Phase III)
- **R&D services:**
 - LMI supplies PET tracers for research projects either at universities or pharma companies, e.g., PI 2620 (Tau)
 - LMI also provides expert services to pharma companies to support them in conducting research and clinical trials with radiopharmaceuticals

*PET = Positron Emission Tomography, an imaging technology used in nuclear medicine to detect radiopharmaceuticals

Making life better

LMI| NEURACEQ® - SALES GROWTH ACCELERATING




- From October 2023 full reimbursement for PET-CT diagnosis for Alzheimers in the US
- Evidenced by acceleration in sales growth after reimbursement decision

Making life better



FINANCIAL REVIEW



H1-2024| RESULTS OVERVIEW



Leading provider of value-based care

Patient-centred care through innovative contracting and reimbursement models



Diversified offering

With an expansion into integral diagnostic and adjacent lines of business



People centred and patient insight driven

Positively impacting patient care through a focus on our employees, clinicians, and the utilisation of data analysis and technology

Strong activity growth in most businesses results in strong revenue growth

Group Revenue

↑ 7.8%

SA Revenue

↑ 5.9%

LMI Revenue

↑ 77.5%

Higher costs not compensated by expected volumes in Q1 result in lower EBITDA

Group normalised EBITDA

↓ -2.8%

SA normalised EBITDA

↓ -4.6%

LMI normalised EBITDA

↑ 68.4%

Lower interest cost results in good earnings growth

NEPS

↑ 8.4%

AMG disposal concluded

Net debt to normalised EBITDA¹
0.8x

Interim dividend
19.0 cents

¹ After special dividend payment of R8.8bn

Making life better

H1-2024| DISPOSAL OF AMG

- AMG is presented as a discontinued operation in the current and prior period
- The disposal was concluded on 31 January 2024 after the completion of all conditions precedent
- Profit on disposal:

▪ Profit recognised in H1-2024	R2 821m
▪ Profit recognised in FY2023	<u>(R990m)</u>
▪ Total profit	<u>R1 831m</u>

- Proceeds were utilised as follows:

	R'm
Gross proceeds	20 054
GBP and EUR debt repaid	(9 070)
Transaction costs and settlement of hedge	(801)
Special distribution paid on 8 April 2024	(8 804)
Investment in FMC paid in April 2024	(367)
Investment in FMC committed	(53)
Investment in LMI committed	(959)

Making life better

H1-2024| STATEMENT OF PROFIT OR LOSS

	2024 R'm	2023 R'm	% change
Revenue	11 741	10 887	7.8
Normalised EBITDA	1 746	1 797	(2.8)
Normalised EBITDA margin	14.9%	16.5%	
EBITA	1 227	1 329	(7.7)
Amortisation	(93)	(75)	24.0
Non-trading net expense	(45)	(22)	
Operating profit	1 089	1 232	(11.6)
Net finance costs	(47)	(335)	86.0
Debt/overdraft	(220)	(271)	18.8
Excess cash	158	33	
Net other	15	(97)	
Associates and joint ventures	4	4	
Profit before tax	1 046	901	16.1
Tax	(311)	(301)	(3.3)
Non-controlling interest	(57)	(78)	
Attributable profit from continuing operations	678	522	29.9

- Results presented include continuing operations. AMG included as part of discontinued operations in current and prior period (excluded from this slide)
- Number of trading days lower in current period as Easter fell in April in PY
- Revenue growth boosted by activity growth in SA of **2.7% PPD growth in acute hospitals** and strong NeuraCeq® doses sold (up 74.4%). Negative mix change in SA impacting Revenue/PPD growth
- SA EBITDA impacted by higher fixed costs and activity levels not at required levels
- Non-trading expense includes transaction costs, fair value loss on financial instruments and loss due to system configuration
- Benefit of de-gearred balance sheet resulting in significant lower interest cost**

Making life better

H1-2024| SEGMENTAL RESULTS

	2024 R'm	2023 R'm	% change
Revenue	11 741	10 887	7.8
Southern Africa	11 228	10 598	5.9
International	513	289	77.5
Normalised EBITDA	1 746	1 797	(2.8)
Southern Africa	1 721	1 797	(4.2)
International	(12)	(38)	68.4
Corporate	37	45	(17.8)
Growth initiatives	-	(7)	
Normalised EBITDA margin (%)	14.9%	16.5%	
Southern Africa (incl. corporate)	15.7%	17.4%	
Southern Africa (excl. corporate)	15.3%	17.0%	
International	(2.3%)	(13.1%)	

	2024 R'm	2023 R'm	% change
Corporate	37	45	(17.8)
Income	852	808	5.4
Costs	(815)	(763)	(6.8)

Making life better

H1-2024 | EARNINGS PER SHARE

	2024	2023	% change
Weighted average number of shares (million)	1 441	1 443	(0.1)
EPS (cents)	242.8	37.9	540.6
Net profit on disposal of AMG	(177.7)	-	
Impairment	-	2.3	
Loss/(profit) on disposal of PPE	0.1	(0.2)	
HEPS (cents)	65.2	40.0	63.0
EPS from continuing operations (cents)	47.1	36.2	30.1
Profit on disposal of PPE	(0.1)	-	
HEPS from continuing operations (cents)	47.0	36.2	29.8
Adjustments to contingent consideration	2.6	1.9	
Interest on SARS VAT matter	-	3.3	
Interest on cash reserved for special distribution	(6.0)	-	
Other	0.5	(0.7)	
NEPS (cents)	44.1	40.7	8.4
NEPS excluding amortisation (cents)	48.9	44.5	9.9

- Total EPS/HEPS impacted by:
 - Net profit on disposal of AMG, which includes an exchange gain realised on the disposal of R3.2 billion
- EPS/HEPS from continuing operations impacted by:
 - Interest received on significant positive cash balance (due to proceeds on sale of AMG) from 1 February 2024

Making life better

H1-2024 | FINANCIAL POSITION

	Mar 2024 R'm	Sep 2023 R'm
Non-current assets	16 219	16 201
Property, plant and equipment	10 512	10 572
Goodwill & Intangibles	3 396	3 287
Other	2 311	2 342
Current assets (excluding cash)	4 665	4 125
Cash	10 149	846
Asset held for sale	-	19 380
Total assets	31 033	40 552
Total shareholders' equity	12 430	21 289
Non-current liabilities	4 362	13 128
Interest-bearing borrowings	2 174	11 010
Other non-current liabilities	2 188	2 118
Current liabilities (excluding int-bearing borrowings)	3 494	4 142
Shareholder for dividend	8 804	-
Interest-bearing borrowings	1 943	1 992
Total equity and liabilities	31 033	40 552
Net debt (post payment of special dividend)	2 772	12 343
Net debt to normalised EBITDA (covenant 3.5x)¹	0.8x	2.00x

- Financial position strengthened
- Special dividend paid 8 April 2024
- Total capex committed for FY2024 excluding acquisitions of R2.3 billion capex

¹ Post special dividend payment of R8.8bn

■ Refinancing of debt

- During April 2024 and May 2024, the Group successfully raised R1.055 billion and R445 million respectively through its Domestic Medium Term Notes (DMTN) programme.
- The Group then early settled R1.25 billion of its South African term debt thereby extending the debt maturities and lower interest rates

	Note LHC03	Note LHC04	Note LHC05	Term debt settled
Amount in ZAR	725	330	445	1 250
Interest rate	3m JIBAR +1.15%	3m JIBAR +1.32%	3m JIBAR +1.32%	3m JIBAR +1.65%
Maturity date	April 2027	April 2029	June 2029	May 2024

- Debt repayment schedule after refinancing in April:

R'm	Balance at 30 April 2024	Maturing in FY2024	Maturing in FY2025	Maturing in FY2026	Maturing in FY2027	Maturing in FY2028 or later
Bank debt	2 836	(156)	(812)	(313)	(1 225)	(330)
Lease liabilities	1 060	(357)	(111)	(117)	(63)	(412)
Total debt	3 896	(513)	(923)	(430)	(1 288)	(742)

Making life better

H1-2024 | CASH FLOW FROM CONTINUING OPERATIONS

	2024 R'm	2023 R'm	% change
Cash generated from operations	1 028	269	>100%
Transaction costs paid	(5)	-	
Net interest paid	(133)	(218)	
Tax paid	(207)	(270)	
Maintenance capex	(580)	(425)	
Minority distributions	(125)	(138)	
Employee share schemes	(206)	(65)	
Free cash flow	(228)	(847)	73.1
Growth capex	(144)	(220)	
Investments and contingent consideration paid	(75)	(59)	
Net cash flow after capex and investments	(447)	(1 126)	60.3
Disposal of AMG, net of costs*	19 376	-	
Repayment of interest-bearing borrowings	(9 048)	(333)	
Dividends paid to Company's shareholders	(396)	(369)	
Other	5	(20)	
Net decrease in cash and cash equivalents from continuing operations	9 490	(1 848)	>100%

- Cash generated from operations in prior period impacted by an IT hardware failure at a service provider which hosts the Group's billing administration system
- Repaid all GBP and EUR debt with proceeds on disposal of AMG

*Cash proceeds (R20 054m) less settlement of hedge (R121m) less transaction costs paid (R557m)

FY2024| CAPITAL ALLOCATION & INVESTING FOR GROWTH

		Southern Africa	LMI
Growth capex	Organic growth and innovation opportunities	<ul style="list-style-type: none"> Facility expansions covering: (2024/2025) <ul style="list-style-type: none"> ICU / HC beds: 59 General ward: 46 Acute rehabilitation: 24 Vascular and cardiac labs: 4 Renal and other VBC products Oncology network of excellence strategy Diagnostic and molecular imaging 	<ul style="list-style-type: none"> LMI <ul style="list-style-type: none"> Small capex for manufacturing kits for NeuraCeq® Additional approvals in other markets Pipeline investments in a carefully stage-gated manner
	Inorganic growth opportunities	<ul style="list-style-type: none"> Additional SA imaging acquisitions Renal dialysis opportunities R350 million hospital property acquisition 	<ul style="list-style-type: none"> Unlikely to pursue mergers and acquisitions (M&A)
FY24 capex committed		R940 million	R220 million

Making life better

FY2024| CAPITAL ALLOCATION & INVESTING FOR GROWTH

		Southern Africa	LMI
Maintenance capex	Grow and sustain existing businesses	<ul style="list-style-type: none"> Embedded footprint <ul style="list-style-type: none"> Organic volume growth Drive optimal occupancy levels Optimise current portfolio of facilities and beds 	<ul style="list-style-type: none"> Small capex requirement for LMI
	FY24 capex committed	<ul style="list-style-type: none"> R1.2 billion 	
	FY24 capex total	<ul style="list-style-type: none"> R2.1 billion 	<ul style="list-style-type: none"> R0.2 billion
Excess cash	Return to shareholders	<ul style="list-style-type: none"> Ordinary dividends - 2024 interim dividend: +11.8% to 19 cps (R279m) Special dividends - AMG dividend: 600 cps (R8.8bn) 	

Making life better



H2 OUTLOOK



NATIONAL HEALTH INSURANCE (NHI) ACT

- Life Healthcare have over the years engaged constructively on NHI and we have made our position clear: we unequivocally support the outcomes visualised by the Act, quality healthcare services for all.
- The focus of our engagement to date and in future will be to enable the sensible introduction of NHI, and to ensure that expanding access to healthcare is achieved sustainably, without compromising the essential healthcare delivery platform or harming the entire healthcare system - this remains unchanged.
- However, the approval of the Bill without addressing concerns raised during the parliamentary process, is a regrettable missed opportunity to expand sustainable access to healthcare. We, therefore, expect a lengthy implementation journey of NHI due to operational and legislative changes required, as well as the current fiscal constraints.
- The proposed healthcare reform decisions within the NHI Act will profoundly impact the sustainability of South Africa's health system for generations to come. On that basis, as a significant healthcare provider, who delivers the highest standards of private healthcare, we will continue to contribute meaningfully to the envisaged extensive legislative reforms of the NHI Act.
- We are monitoring the developments on the NHI Act as well as related legislation and will explore all avenues to ensure the sustainability of the healthcare industry. Life Healthcare's commitment lies in acting in the best interests of our doctors, nurses and our patients, both current and future.

Making life better



Leading provider of value-based care

Patient-centred care through innovative contracting and reimbursement models



Diversified offering

With an expansion into integral diagnostic and adjacent lines of business



People centred and patient insight driven

Positively impacting patient care through a focus on our employees, clinicians, and the utilisation of data analysis and technology

Southern Africa	<ul style="list-style-type: none">▪ Occupancies at 70%▪ Targeting PPD growth of c.2%▪ Continuing improvement of EBITDA margin from H1-2024▪ Detailed focus on operational efficiencies▪ Continued emphasis on non-acute business opportunities▪ Additional imaging transactions already underway▪ Finalise and operationalise FMC renal acquisition
Life Molecular Imaging	<ul style="list-style-type: none">▪ Increase NeuraCeq® commercial sales

Making life better



QUESTIONS

